The Applicant proposed a restriction of the applied indication to the HRc+ population and claimed that a clinically meaningful improvement is clearly demonstrated in this subgroup. The applicant considered this subgroup, as ascertained as a stratification factor, to be an appropriate, robust subgroup to propose as the indication population.